Assessment of fluence- and dose-averaged linear energy transfer with passive luminescence detectors in clinical proton beams

Objective.This work investigates the use of passive luminescence detectors to determine different types of averaged linear energy transfer (LET-) for the energies relevant to proton therapy. The experimental results are compared to reference values obtained from Monte Carlo simulations.Approach.Optically stimulated luminescence detectors (OSLDs), fluorescent nuclear track detectors (FNTDs), and two different groups of thermoluminescence detectors (TLDs) were irradiated at four different radiation qualities. For each irradiation, the fluence- (LET-f) and dose-averaged LET (LET-d) were determined. For both quantities, two sub-types of averages were calculated, either considering the contributions from primary and secondary protons or from all protons and heavier, charged particles. Both simulated and experimental data were used in combination with a phenomenological model to estimate the relative biological effectiveness (RBE).Main results.All types ofLET-could be assessed with the luminescence detectors. The experimental determination ofLET-fis in agreement with reference data obtained from simulations across all measurement techniques and types of averaging. On the other hand,LET-dcan present challenges as a radiation quality metric to describe the detector response in mixed particle fields. However, excluding secondaries heavier than protons from theLET-dcalculation, as their contribution to the luminescence is suppressed by ionization quenching, leads to equal accuracy betweenLET-fandLET-d. Assessment of RBE through the experimentally determinedLET-dvalues agrees with independently acquired reference values, indicating that the investigated detectors can determineLET-with sufficient accuracy for proton therapy.Significance.OSLDs, TLDs, and FNTDs can be used to determineLET-and RBE in proton therapy. With the capability to determine dose through ionization quenching corrections derived fromLET-, OSLDs and TLDs can simultaneously ascertain dose,LET-, and RBE. This makes passive detectors appealing for measurements in phantoms to facilitate validation of clinical treatment plans or experiments related to proton therapy.

Surface dose measurement and comparison between TLD and OSLD during modified re constructive mastectomy irradiation

Radiotherapy (RT) is one of the major treatment modalities among surgery and chemotherapy for carcinoma breast. The surface dose study of modified reconstructive constructive Mastectomy (MRM) breast is important due to the heterogeneity in the body contour and the conventional treatment angle to save the lungs and heart from the radiation. These angular entries of radiation beam cause an unpredictable dose deposition on the body surface, which has to be monitored. Thermoluminescent dosimeter (TLD) or optically stimulated luminescent dosimeter (nano OSLD) are commonly preferable dosimeters for this purpose. The surface dose response of TLD and nano OSLD during MRM irradiation has been compared with the predicted dose from the treatment planning system (TPS). The study monitored 100 MRM patients by employing a total 500 dosimeters consisting of TLD (n = 250) and nano OSLD (n = 250), during irradiation from an Elekta Versa HD 6 MV Linear accelerator. The study observed a variance of 3.9% in the dose measurements for TLD and 3.2% for nano OSLD from the planned surface dose, with a median percentage dose of 44.02 for nano OSLD and 40.30 for TLD (p value 0.01). There was no discernible evidence of variation in dose measurements attributable to differences in field size or from patient to patient. Additionally, no variation was observed in dose measurements when comparing the placement of the dosimeter from central to off-centre positions. In comparison, a minor difference in dose measurements were noted between TLD and nano OSLD, The study's outcomes support the applicability of both TLD and nano OSLD as effective dosimeters during MRM breast irradiation for surface dose evaluation.

Population Effectiveness of Dolutegravir Implementation in Uganda - A Prospective Observational Cohort Study (DISCO): 48-week Results

BACKGROUND

Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on non-nucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics.

METHODS

We conducted a prospective cohort study of PWH ≥18 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24- and 48- weeks later. The primary endpoint was viral suppression (<200 copies/mL) at 48-weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL >500 copies/mL.

RESULTS

We enrolled 500 participants (median age of 47 years; 41% women). At 48-weeks after TLD transition, 94% of participants were in care with a VL <200 copies/mL (n = 469/500); 2% (n = 11/500) were lost from care or died; and only 2% (n = 9/500) had a VL >500 copies/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9/500) discontinued TLD due to adverse events.

CONCLUSIONS

High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region.

Thermoluminescence dosimetry (TLD) in a 3 T magnetic resonance imaging (MRI) environment: implications for personnel exposure monitoring

Thermoluminescent dosimeters (TLDs) serve as compact and user-friendly tools for various applications, including personal radiation dosimetry and radiation therapy. This study explores the potential of utilizing TLD-100 personal dosimetry, conventionally applied in PET/CT (positron emission tomography/computed tomography) settings, in the PET/MRI (magnetic resonance imaging) environment. The integration of MRI into conventional radiotherapy and PET systems necessitates ionizing radiation dosimetry in the presence of static magnetic fields. In this study, TLD-100 dosimeters were exposed on the surface of a water-filled cylindrical phantom containing PET-radioisotope and positioned on the patient table of a 3 T PET/MRI, where the magnetic field strength is around 0.2 T, aiming to replicate real-world scenarios experienced by personnel in PET/MRI environments. . Results indicate that the modified MR-safe TLD-100 personal dosimeters exhibit no significant impact from the static magnetic field of the 3 T PET/MRI, supporting their suitability for personal dosimetry in PET/MRI settings. This study addresses a notable gap in existing literature on the effect of MRI static magnetic field on TLDs.

Experimental Testing on Tuned Liquid Dampers for Implementation in Industrial Chimneys

A TLD is a passive damping device that works by dissipating energy through the sloshing of the liquid and the effect of wave breaking, thereby controlling the vibrations of the structure. One of the applications where TLDs are of great interest is in the case of industrial chimneys since these structures often have a very low natural frequency, which can be easily achieved in a control device of this type. The main objective of this study is to evaluate the behaviour of an annular TLD composed of multiple cells through laboratory tests and investigate if it is adequate to design it as an agglomeration of smaller rectangular TLDs. The influence of the amplitude of displacement on the behaviour of the annular TLD will also be analysed. The tests were performed on a shaking table and recurring with pendulums of the same length but of different masses. Three reservoirs were studied as TLDs: a rectangular one, a cell of an annular TLD and a quarter-ring of an annular TLD. This study concluded that the analytical methods developed in previous studies were, in general, adequate for the design of a rectangular TLD and that it was reasonable to design the annular TLD studied as a combination of rectangular ones, as its cells were a close match to a rectangle of similar dimensions. It was also concluded that a compartmentalised annular TLD is an adequate solution for the vibration control of structures with high displacements.

Episodic Presentations of Pustular Pyoderma Gangrenosum in PLHIV: A Case Report and Brief Review of Literature

We report a case of a 54-year-old female diagnosed with HIV and antiretroviral therapy (ART) for the same. Seven years ago, she suffered from fever, cough and weight loss, was diagnosed with pulmonary tuberculosis and also seropositive for HIV. She suffered from Herpes Zoster infection, after which her ART regimen was changed to TLD (tenofovir, lamivudine and dolutegravir). The patient presented with two episodes of pyoderma gangrenosum (PG), which were biopsy-proven, corresponding to a rise in CD4 counts above 500. She responded to glucocorticoids, both systemic and topical.

Technical note: High-dose and ultra-high dose rate (UHDR) evaluation of Al2 O3 :C optically stimulated luminescent dosimeter nanoDots and powdered LiF:Mg,Ti thermoluminescent dosimeters for radiation therapy applications

BACKGROUND

Dosimetry in ultra-high dose rate (UHDR) electron beamlines poses a significant challenge owing to the limited usability of standard dosimeters in high dose and high dose-per-pulse (DPP) applications.

PURPOSE

In this study, Al2 O3 :C nanoDot optically stimulated luminescent dosimeters (OSLDs), single-use powder-based LiF:Mg,Ti thermoluminescent dosimeters (TLDs), and Gafchromic EBT3 film were evaluated at extended dose ranges (up to 40 Gy) in conventional dose rate (CONV) and UHDR beamlines to determine their usability for calibration and dose verification in the setting of FLASH radiation therapy.

METHODS

OSLDs and TLDs were evaluated against established dose-rate-independent Gafchromic EBT3 film with regard to the potential influence of mean dose rate, instantaneous dose rate, and DPP on signal response. The dosimeters were irradiated at CONV or UHDR conditions on a 9-MeV electron beam. Under UHDR conditions, different settings of pulse repetition frequency (PRF), pulse width (PW), and pulse amplitude were used to characterize the individual dosimeters' response in order to isolate their potential dependencies on dose, dose rate, and DPP.

RESULTS

The OSLDs, TLDs, and Gafchromic EBT3 film were found to be suitable at a dose range of up to 40 Gy without any indication of saturation in signal. The response of OSLDs and TLDs in UHDR conditions were found to be independent of mean dose rate (up to 1440 Gy/s), instantaneous dose rate (up to 2 MGy/s), and DPP (up to 7 Gy), with uncertainties on par with nominal values established in CONV beamlines (± 4%). In cross-comparing the response of OSLDs, TLDs and Gafchromic film at dose rates of 0.18-245 Gy/s, the coefficient of variation or relative standard deviation in the measured dose between the three dosimeters (inter-dosimeter comparison) was found to be within 2%.

CONCLUSIONS

We demonstrated the dynamic range of OSLDs, TLDs, and Gafchromic film to be suitable up to 40 Gy, and we developed a protocol that can be used to accurately translate the measured signal in each respective dosimeter to dose. OSLDs and powdered TLDs were shown to be viable for dosimetric measurement in UHDR beamlines, providing dose measurements with accuracies on par with Gafchromic EBT3 film and their concurrent use demonstrating a means for redundant dosimetry in UHDR conditions.

Evaluation of organ and effective doses using anthropomorphic phantom: A comparison between experimental measurement and a commercial dose calculator

INTRODUCTION

The aim of this study was to experimentally measure organ doses for computed tomography (CT) procedures using thermoluminescence dosimeters (TLDs) on a RANDO anthropomorphic phantom and verify the measured doses using CT-Expo software.

METHODS

The phantom was irradiated using clinical CT scan protocols routinely used for specific procedures in the radiology department. Fifty TLD chips were used in this study. The scanning parameters (kVp, mA, s) used to scan the phantom were used as input parameters for CT-Expo dose estimations.

RESULTS

The TLD measured organ doses varied between 3.97 mGy for the esophagus and 56.22 mGy for the brain. High doses were recorded in the brain (37.80-56.22 mGy) and the eye lens (29.94-36.16 mGy). Comparing the organ dose measurements between TLD and CT-Expo, the maximum organ dose difference was obtained for the eye lens. A comparison between the two methods for the other organs were all less than 32 %. The effective doses from the TLD measurements for the head, chest, and abdominopelvic CT examinations were 2.78, 6.67, and 17 mSv, respectively and CT-Expo were 2.20, 10.30, and 16.70 mSv, respectively.

CONCLUSION

The experimental and computational results are comparable, and the reliability of the TLD measurements and CT-Expo dose calculator has been proven.

IMPLICATIONS FOR STUDY

A reason for the difference in dose measurements between the two methods has been attributed to the dissimilarity in the organ position in the Rando anthropomorphic phantom and the standard mathematical phantom used by CT-Expo. The experimental and computational results have been found to be comparable.

Instrumentation for measuring equivalent ambient dose in urban buildings using TLDs

The Thermoluminescent dosimeter is a solid material used as instrumentation for environmental monitoring through determining environmental equivalent dose H∗(10). This work presents the calibration methodology for TLDs LiF:Mg, Cu, P dosimeters and their application to measure H∗(10) in internal buildings occupied by inhabitants of an urban area. The calibration factor and type tests were made according to ISO 4037-3 and IEC 62387, and the uncertainty was determined. The values found are under the reference values. Therefore, the dosimeters can be applied.

Prediction of breast dose in chest CT examinations using adaptive neuro-fuzzy inference system (ANFIS)

In chest computed tomography (CT), the breasts located within the scan range receive a substantial radiation dose. Due to the risk of breast-related carcinogenesis, analyzing the breast dose for justification of CT examinations seems necessary. The main goal of this study is to overcome the limitations of conventional dosimetry methods, such as thermoluminescent dosimeters (TLDs) by introducing the adaptive neuro-fuzzy inference system (ANFIS) approach. In this study, the breast dose of 50 adult female patients who underwent chest CT examinations was measured directly by TLDs. Then, the ANFIS model was developed with four inputs including dose length product (DLP), volumetric CT dose index (CTDIvol), total mAs, and size-specific dose estimate (SSDE), and one output (TLD dose). Additionally, multiple linear regression (MLR) as a traditional prediction model was used for linear modeling and its results were compared with the ANFIS. The TLD reader results showed that the breast dose value was 12.37 ± 2.46 mGy. Performance indices of the ANFIS model, including root mean square error (RMSE) and correlation coefficient (R), were calculated at 0.172 and 0.93 for the testing dataset, respectively. Also, the ANFIS model had superior performance in predicting the breast dose than the MLR model (R = 0.805). This study demonstrates that the proposed ANFIS model is efficient for patient dose prediction in CT scans. Therefore, intelligence models such as ANFIS are suggested to estimate and optimize patient dose in CT examinations.

Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens

Increased HIV drug resistance (HIVDR) with antiretroviral therapy (ART) rollout may jeopardize therapeutic options, especially in this era of transition to fixed-dose tenofovir-lamivudine-dolutegravir (TLD). We studied acquired HIVDR (ADR) patterns and describe potentially active drugs after first- and second-line failure in resource-limited settings (RLS) like Cameroon. A laboratory-based study with 759 patients (≥15 years) experiencing virological failure was carried out at the Chantal Biya International Reference Centre (CIRCB), Yaoundé, Cameroon. Socio-demographic, therapeutic and immunovirological data from patient records were analysed according to HIV-1 genotypic profiles. Median (IQR) ART-duration was 63 (50-308) months. Median CD4 and viremia were 153 (IQR:50-308) cells/mm3 and 138,666 (IQR:28,979-533,066) copies/mL, respectively. Overall ADR was high (93.4% first-line; 92.9%-second-line). TDF, potentially active in 35.7% of participants after first-line and 45.1% after second-line, suggested sub-optimal TLD-efficacy in second-line (64.3%) and third-line (54.9%). All PI/r preserved high efficacy after first-line failure while only DRV/r preserved high-level efficacy (87.9%) after second-line failure. In this resource-limited setting (RLS), ADR is high in ART-failing patients. PI/r strategies remain potent backbones for second-line ART, while only DRV/r remains very potent despite second-line failure. Though TLD use would be preferable, blind use for second- and third-line regimens may be sub-optimal (functional monotherapy with dolutegravir) with high risk of further failure, thus suggesting strategies for selective ART switch to TLD in failing patients in RLS.

Impact of the Frequency and Type of Procedures Performed in Nuclear Medicine Units on the Expected Radiological Hazard

Nuclear medicine procedures play an important role in medical diagnostics and therapy. They are related to the use of ionizing radiation, which affects the radiological exposure of all of the persons involved in their performance. The goal of the study was to estimate the doses associated with the performance of various nuclear medicine procedures in order to optimize workload management. The analysis was performed for 158 myocardial perfusion scintigraphy procedures, 24 bone scintigraphies, 9 thyroid scintigraphies (6 with use of ¹³¹I and 3 with ^99mTc), 5 parathyroid glands and 5 renal scintigraphies. In this evaluation, two possible locations of thermoluminescent detectors, used for measurements, were taken into consideration: in the control room and directly next to the patient. It was shown how the radiological exposure varies depending on the performed procedure. For high activity procedures, ambient dose equivalent registered in the control room reached the level over 50% of allowed dose limit. For example, ambient dose equivalent obtained in control room when performing bone scintigraphy only was 1.13 ± 0.3 mSv. It is 68% of calculated dose limit in the examined time span. It has been shown that risk associated with nuclear medicine procedures is influenced not only by the type of procedure, but also by the frequency of their performance and compliance with the ALARA principle. Myocardial perfusion scintigraphy accounted for 79% of all evaluated procedures. The use of radiation shielding reduced the obtained doses from 14.7 ± 2.1 mSv in patient's vicinity to 1.47 ± 0.6 mSv behind the shielding. By comparing the results obtained for procedures and dose limits established by Polish Ministry of Health, it is possible to estimate what should be the optimal division of duties between staff, so that everyone receives similar doses.

Evaluation occupationally radiation exposure during diagnostic imaging examinations

Occupational radiation exposure can occur due to various human activities, including the use of radiation in medicine. Occupationally exposed personnel surpassing 7.4 millions, and respresent the biggest single group of employees who are exposed to artificial radiation sources at work. This study compares the occupational radiation dose levels for 145 workers in four different hospitals located in the Aseer region in Saudi Arabia. The occupational exposure was quantified using thermoluminescence dosimeters (TLD-100). The levels of annual occupational exposures in targeted hospitals were calculated and compared with the levels of the international atomic energy agency (IAEA) Safety Standards. An average yearly cumulative dose for the two consecutive years. The average, highest and lowest resulted occupational doses under examination in this work is 1.42, 3.9 mSv and 0.72 for workers in various diagnostic radiology procedures. The resulted annual effective dose were within the IAEA approved yearly dose limit for occupational exposure of workers over 18, which is 20 mSv. Staff should be monitored on a regular basis, according to current practice, because their annual exposure may surpass 15% of the annual effective doses.

Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model

To ensure optimal prescribing practices in the dolutegravir-era in Cameroon, we compared first-line virological response (VR) under tenofovir + lamivudine + dolutegravir (TLD) according to prior exposure to tenofovir + lamivudine + efavirenz (TLE). A facility-based survey was conducted among patients initiating antiretroviral therapy (ART) with TLD (I-TLD) versus those transitioning from TLE to TLD (T-TLD). HIV viral load was performed and unsuppressed participants (VL > 1000 copies/mL) had genotyping performed by Sanger sequencing. Of the 12,093 patients followed, 310 (mean-age: 41 ± 11 years; 52.26% female) complied with study criteria (171 I-TLD vs. 139 T-TLD). The median ART-duration was 14 (12−17) months among I-TLDs versus 28 (24.5−31) months among T-TLDs (15 (11−19) on TLE and 14 (9−15) on TLD), and 83.15% (148/178) were at WHO clinical stages I/II. The viral suppression rate (<1000 copies/mL) was 96.45%, with 97.08% among I-TLDs versus 95.68% among T-TLDs (p = 0.55). VR was similar in I-TLD versus T-TLD at <400 copies/mL (94.15% versus 94.42%) and age, gender, residence, ART-duration, and WHO stages were not associated with VR (p > 0.05). Genotyping was successful for 72.7% (8/11), with no major mutations to integrase inhibitors found. VR is optimal under first-line TLD after 14 months, even among TLE-exposed, thus confirming the effectiveness of transitioning from TLE to TLD in similar settings, supported by strong pharmacological potency and genetic barrier of dolutegravir.

Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT

A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D²EFT is an open-label randomised controlled non-inferiority phase IIIB/IV trial in people living with HIV-1 (PWH) whose first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is failing. At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir. Implemented in 2017, participating sites were across Africa, Asia and Latin America. Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD). This situation pushed D²EFT investigators to consider the impact of the roll-out of TLD on the D²EFT research question. The protocol team agreed it was important to study TLD in second-line when an NNRTI regimen was failing, and focused on options to expedite the work by studying the question within the existing trial and network. All key issues (statistical, programmatic and financial) were reviewed to assess the benefits and risks of adding a third arm to the ongoing study, as opposed to developing a new randomised clinical trial with the same control arm and within the same network. The development of a new trial was deemed to be longer than adding a third arm, and to create a challenging situation with two competing clinical trials at the same sites which would slow down recruitment and impair both trials. On the other hand, adding a third arm would be demanding in terms of operationalisation, increased sample size and statistical biases to control. The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial design to achieve statistical validity. The D²EFT study maintains additional value in a quickly evolving second-line ART strategy allowed by the progress in global access to ART.

Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa

INTRODUCTION

In 2019, the World Health Organization (WHO) recommended tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD) as the preferred first line regimen for adults and adolescents regardless of childbearing status. Nevertheless, final eligibility is determined by local policies which may vary from WHO recommendations. We examined TLD transition by gender across five PEPFAR-supported HIV care programs in sub-Saharan Africa.

METHODS

The African Cohort Study (AFRICOS) enrolls people living with HIV (PLWH) engaged in care in Uganda, Kenya (South Rift Valley and Kisumu West), Tanzania and Nigeria. PLWH with at least one study visit after the country introduced TLD were included. We generated Kaplan-Meier (KM) curves to compare TLD transition by gender from 1) time countries' introduction of TLD and 2) time of TLD eligibility according to local policies.

RESULTS

Among 2.476 participants enrolled through September 2021 at 4 sites in sub-Saharan Africa and eligible to transition to TLD, fewer women (68%) compared to men (80%, p < 0.001) were taking TLD. Kaplan-Meier analysis showed time to transition varied by site, with women in Tanzania transitioning at the same rate as men. In Nigeria, women initially had a slower transition but caught up to men. After adjusting for local policies, women[1] in Kisumu West transitioned at the same rate as men. In South Rift Valley and Uganda, women were less likely to be transitioned.

CONCLUSIONS

Despite TLD being the WHO's preferred regimen since 2019, transition of women to potentially lifesaving TLD has been slower than men at certain clinical sites even after accounting for local eligibility criteria.

Validation of a Monte Carlo Framework for Out-of-Field Dose Calculations in Proton Therapy

Proton therapy enables to deliver highly conformed dose distributions owing to the characteristic Bragg peak and the finite range of protons. However, during proton therapy, secondary neutrons are created, which can travel long distances and deposit dose in out-of-field volumes. This out-of-field absorbed dose needs to be considered for radiation-induced secondary cancers, which are particularly relevant in the case of pediatric treatments. Unfortunately, no method exists in clinics for the computation of the out-of-field dose distributions in proton therapy. To help overcome this limitation, a computational tool has been developed based on the Monte Carlo code TOPAS. The purpose of this work is to evaluate the accuracy of this tool in comparison to experimental data obtained from an anthropomorphic phantom irradiation. An anthropomorphic phantom of a 5-year-old child (ATOM, CIRS) was irradiated for a brain tumor treatment in an IBA Proteus Plus facility using a pencil beam dedicated nozzle. The treatment consisted of three pencil beam scanning fields employing a lucite range shifter. Proton energies ranged from 100 to 165 MeV. A median dose of 50.4 Gy(RBE) with 1.8 Gy(RBE) per fraction was prescribed to the initial planning target volume (PTV), which was located in the cerebellum. Thermoluminescent detectors (TLDs), namely, Li-7-enriched LiF : Mg, Ti (MTS-7) type, were used to detect gamma radiation, which is produced by nuclear reactions, and secondary as well as recoil protons created out-of-field by secondary neutrons. Li-6-enriched LiF : Mg,Cu,P (MCP-6) was combined with Li-7-enriched MCP-7 to measure thermal neutrons. TLDs were calibrated in Co-60 and reported on absorbed dose in water per target dose (μGy/Gy) as well as thermal neutron dose equivalent per target dose (μSv/Gy). Additionally, bubble detectors for personal neutron dosimetry (BD-PND) were used for measuring neutrons (>50 keV), which were calibrated in a Cf-252 neutron beam to report on neutron dose equivalent dose data. The Monte Carlo code TOPAS (version 3.6) was run using a phase-space file containing 10¹⁰ histories reaching an average standard statistical uncertainty of less than 0.2% (coverage factor k = 1) on all voxels scoring more than 50% of the maximum dose. The primary beam was modeled following a Fermi–Eyges description of the spot envelope fitted to measurements. For the Monte Carlo simulation, the chemical composition of the tissues represented in ATOM was employed. The dose was tallied as dose-to-water, and data were normalized to the target dose (physical dose) to report on absorbed doses per target dose (mSv/Gy) or neutron dose equivalent per target dose (μSv/Gy), while also an estimate of the total organ dose was provided for a target dose of 50.4 Gy(RBE). Out-of-field doses showed absorbed doses that were 5 to 6 orders of magnitude lower than the target dose. The discrepancy between TLD data and the corresponding scored values in the Monte Carlo calculations involving proton and gamma contributions was on average 18%. The comparison between the neutron equivalent doses between the Monte Carlo simulation and the measured neutron doses was on average 8%. Organ dose calculations revealed the highest dose for the thyroid, which was 120 mSv, while other organ doses ranged from 18 mSv in the lungs to 0.6 mSv in the testes. The proposed computational method for routine calculation of the out-of-the-field dose in proton therapy produces results that are compatible with the experimental data and allow to calculate out-of-field organ doses during proton therapy.

A comparison of effective dose and risk for different collimation options used in AP shoulder radiography

INTRODUCTION

Radiography forms the cornerstone of the evaluation of shoulder disorders. While the benefits of radiography exceed the risks, there continues to be a compelling case for reduction of radiation exposure from diagnostic radiography. The aim of this project was to evaluate the radiation dose and risk for a variety of collimation settings used during anteroposterior (AP) shoulder radiography.

METHODS

This was a phantom based study where an ATOM adult dosimetry phantom was loaded with 272 thermoluminescent dosimeters (TLDs). Following loading, the phantom was setup for an AP shoulder X-ray projection with standard 25 × 30 cm rectangular collimation. The phantom was exposed three times and then the TLDs were removed and read. The experiment was repeated using a diamond shaped collimation and rectangular collimation with a minimum field of view to portray only relevant anatomy. Using the TLD dose measurements the effective doses and radiation risks were determined and compared.

RESULTS

As expected, organs neighbouring the shoulder experienced the highest absorbed doses (greater than 0.01 mGy); these organs included breast, lung and thyroid gland. The effective doses for standard rectangular, small rectangular and diamond collimation were 0.011, 0.008 and 0.016 mSv, respectively. When compared to standard collimation, a small field of view reduced effective dose by 27.3% and when moving to a diamond shape there was a 45.5% increase. The differences are likely driven by differences in the coverage of the radiosensitive lung and breast tissue.

CONCLUSION

By utilising a variety of different collimation settings, effective dose can be reduced. Reducing the radiation dose is both financially beneficial and results in a lower stochastic risk for patients. Image quality must also be considered when choosing different collimation settings. It stands to reason that by reducing the field size, dose will be reduced, and our study has served to quantify the effects in a practical situation.

IMPLICATIONS FOR PRACTICE

The utilisation of smaller/tight collimation is recommended as it offers the lowest dose when compared with other types of collimations. Although well-known this study serves to remind practitioners of the practical importance of collimation and is associated effect on effective dose and risk.

Nuclear medicine staff exposure to ionising radiation in 18F-FDG PET/CT practice: a preliminary retrospective study

This retrospective study provides an insight into the levels of radiation exposure of six nuclear medicine (NM) staff (four technologists and two nurses) performing routine diagnostic ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography-computed tomography (PET/CT) at the University Clinical Centre of the Republic of Srpska, Department of Nuclear Medicine and Thyroid Disorders, Banja Luka, Bosnia and Herzegovina. Data analysis included monthly staff exposure measured with personal thermoluminescent dosimeters (TLD) between June and December 2018, quantified in terms of normalised dose for the whole body [Hp(10)] and dominant hand [Hp(0.07)] and their comparison between each staff member and between the two groups (technologists and nurses). The study goal was to establish how our Department compared with reports from other PET/CT centres worldwide in terms of annual number of procedures and exposure limits and whether there could be room for further improvements in radiation protection. The number of procedures rose considerably from 208 in 2016 to 876 in 2019 and was 423 in the observed seven-month period. Mean individual whole-body exposure dose per GBq of injected ¹⁸F-FDG activity, [Hp(10)/A] was 18.55 μSv/GBq for the four technologists and 15.61 μSv/GBq for the two nurses. Mean dominant-hand exposure dose per GBq of injected ¹⁸F-FDG activity [Hp(0.07)/A] was 16.99 μSv/GBq and 25.44 μSv/GBq for the two groups, respectively. The average annual cumulative dose for all staff was (1.06±0.29) mSv for Hp(10) and (1.15±0.32) mSv for Hp(0.07). These results are comparable with those of similar studies. Staff doses were well below the annual limits. Nurses received slightly higher extremity doses than technologists. In view of the increasing trends in the number of PET/CT procedures, dose monitoring should be continued to identify exposure hotspots and maintain doses as low as possible.

Dosimetry on first clinical dark-field chest radiography

PURPOSE

The purpose of this study was to evaluate the dose characteristic for patient examinations at the first clinical X-ray dark-field chest radiography system and to determine whether the effective patient dose is within a clinically acceptable dose range.

METHODS

A clinical setup for grating-based dark-field chest radiography was constructed and commissioned, operating at a tube voltage of 70 kVp. Thermoluminescent dosimeter (TLD) measurements were conducted using an anthropomorphic phantom modeling the reference person to obtain a conversion coefficient relating dose area product (DAP) to effective patient dose at the dark-field system. For 92 patients, the DAP values for posterior-anterior measurements were collected at the dark-field system. Using the previously determined conversion coefficient, the effective dose was calculated.

RESULTS

A reference person, modeled by an anthropomorphic phantom, receives an effective dose of 35 µSv. For the examined patients, a mean effective dose of 39 µSv was found.

CONCLUSIONS

The effective dose at the clinical dark-field radiography system, generating both attenuation and dark-field images, is within the range of reported standard dose values for chest radiography.

Technical Note: On the feasibility of performing dosimetry in target and organ at risk using polymer dosimetry gel and thermoluminescence detectors in an anthropomorphic, deformable, and multimodal pelvis phantom

OBJECTIVE

To assess the feasibility of performing dose measurements in the target (prostate) and an adjacent organ at risk (rectum) using polymer dosimetry gel and thermoluminescence detectors (TLDs) in an anthropomorphic, deformable, and multimodal pelvis phantom (ADAM PETer).

METHODS

The 3D printed prostate organ surrogate of the ADAM PETer phantom was filled with polymer dosimetry gel. Nine TLD600 (LiF:Mg,Ti) were installed in 3 × 3 rows on a specifically designed 3D-printed TLD holder. The TLD holder was inserted into the rectum at the level of the prostate and fixed by a partially inflated endorectal balloon. Computed tomography (CT) images were taken and treatment planning was performed. A prescribed dose of 4.5 Gy was delivered to the planning target volume (PTV). The doses measured by the dosimetry gel in the prostate and the TLDs in the rectum ("measured dose") were compared to the doses calculated by the treatment planning system ("planned dose") on a voxel-by-voxel basis.

RESULTS

In the prostate organ surrogate, the 3D-γ-index was 97.7% for the 3% dose difference and 3 mm distance to agreement criterium. In the center of the prostate organ surrogate, measured and planned doses showed only minor deviations (<0.1 Gy, corresponding to a percentage error of 2.22%). On the edges of the prostate, slight differences between planned and measured doses were detected with a maximum deviation of 0.24 Gy, corresponding to 5.3% of the prescribed dose. The difference between planned and measured doses in the TLDs was on average 0.08 Gy (range: 0.02-0.21 Gy), corresponding to 1.78% of the prescribed dose (range: 0.44%-4.67%).

CONCLUSIONS

The present study demonstrates the feasibility of using polymer dosimetry gel and TLDs for 3D and 1D dose measurements in the prostate and the rectum organ surrogates in an anthropomorphic, deformable and multimodal phantom. The described methodology might offer new perspectives for end-to-end tests in image-guided adaptive radiotherapy workflows.

Modelling and measurements of distributions in an adult human phantom undergoing proton scanning beam radiotherapy: lung- and prostate-located tumours

Proton radiotherapy has been shown to offer a significant dosimetric advantage in cancer patients, in comparison to conventional radiotherapy, with a decrease in dose to healthy tissue and organs at risk, because the bulk of the beam energy is deposited in the Bragg peak to be located within a tumour. However, it should be kept in mind that radiotherapy of cancer is still accompanied by adverse side effects, and a better understanding and improvement of radiotherapy can extend the life expectancy of patients following the treatment of malignant tumours. In this study, the dose distributions measured with thermoluminescent detectors (TLDs) inside a tissue-equivalent adult human phantom exposed for lung and prostate cancer using the modern proton beam scanning radiotherapy technique were compared. Since the TLD detection efficiency depends on the ionization density of the radiation to be detected, and since this efficiency is detector specific, four different types of TLDs were used to compare their response in the mixed radiation fields. Additionally, the dose distributions from two different cancer treatment modalities were compared using the selected detectors. The measured dose values were benchmarked against Monte Carlo simulations and available literature data. The results indicate an increase in the lateral dose with an increase of the primary proton energy. However, the radiation quality factor of the mixed radiation increases by 20% in the vicinity to the target for the lower initial proton energy, due to the production of secondary charged particles of low-energy and short range. For the cases presented here the MTS-N TLD detector seems to be the most optimal tool for dose measurements within the target volume, while the MCP-N TLD detector, due to an interplay of its enhanced thermal neutron response and decreased detection efficiency to highly ionising radiation, is a better choice for the out-of-field measurements. The pairs of MTS-6 and MTS-7 TLDs used also in this study allowed for a direct measurement of the neutron dose equivalent. Before it can be concluded that they offer an alternative to the time-consuming nuclear track detectors, however, more research is needed to unambiguously confirm whether this observation was just accidental or whether it only applies to certain cases. Since there is no universal detector, which would allow the determination of the dosimetric quantities relevant for risk estimation, this work expands the knowledge necessary to improve the quality of dosimetry data and might help scientists and clinicians in choosing the right tools to measure radiation doses in mixed radiation fields.

Response of TLD-600/TLD-700 and CR-39 to neutrons for medical dosimetry

In this study, thermoluminescence detectors (TLD)-600 and TLD-700 were used under different conditions to study neutron dosimetry for its application in medical dosimetry as albedo dosimeters. ⁶ LiF has a high cross-section for neutrons and is more sensitive to neutrons than to gamma radiation. Conversely, TLD-700 showed a better response to gamma radiation. Therefore, to obtain the response for neutrons, the responses for TLD-600 and TLD-700 were subtracted. A cadmium sheet was used to absorb incident thermal neutrons so that detector measured only backscattered neutrons from the albedo dosimeter. A Perspex sheet was used as a moderator to thermalize the fast neutron source Am-Be used in the experiment. CR-39 was used to detect fast neutrons and act as an albedo dosimeter when covered with a ¹⁰ B disc. Both TLD and CR-39 dosimeters were successful in detecting scattered neutrons in radiotherapy rooms.

Ambient and personnel occupational dose assessment in a Hospital's PET/CT center

This study used thermoluminescent dosimeters (TLDs) to measure cumulative radiation doses in a PET/CT center. It covered 18 areas and four personnel groups. Because the isolated lead shielding separated the patients from the nurses, wearing protective clothing when injecting radiopharmaceuticals was unnecessary. Fingertip doses of the dispensing and nurse groups were below the occupational limit. Current radiopharmaceutical transportation and injection operations in this PET/CT center provide considerable radiation protection to medical personnel.

End-to-end dosimetric audit: A novel procedure developed for Irish HDR brachytherapy centres

PURPOSE

A dosimetric audit of Ir-192 high dose rate (HDR) brachytherapy remote after-loading units was carried out in 2019. All six brachytherapy departments on the island of Ireland participated in an end-to-end test and in a review of local HDR dosimetry procedures.

MATERIALS AND METHODS

A 3D-printed customised phantom was created to position the following detectors at known distances from the HDR source: a Farmer ionization chamber, GafChromic film and thermoluminescent dosimeters (TLDs). Dedicated HDR applicator needles were used to position an Ir-192 source at 2 cm distance from these detectors. The end-to-end dosimetry audit pathway was performed at each host site and included the stages of imaging, applicator reconstruction, treatment planning and delivery. Deviations between planned and measured dose distributions were quantified using gamma analysis methods. Local procedures were also discussed between auditors and hosts.

RESULTS

The mean difference between Reference Air Kerma Rate (RAKR) measured during the audit and RAKR specified by the vendor source certificate was 1.3%. The results of end-to-end tests showed a mean difference between calculated and measured dose of 2.5% with TLDs and less than 0.5% with Farmer chamber measurements. GafChromic films showed a mean gamma passing rates of >95% for plastic and metal applicators with 2%/1 mm global tolerance criteria.

CONCLUSIONS

The results of this audit indicate dosimetric consistency between centres. The 'end to end' dosimetry audit methodology for HDR brachytherapy has been successfully implemented in a multicentre environment, which included different models of Ir-192 sources and different treatment planning systems. The ability to create a 3D-printed water-equivalent phantom customised to accurately position all three detector types simultaneously at controlled distances from the Ir-192 source under evaluation gives good reproducibility for end-to-end methodology.